Answers are grounded in this paper and cite their sources.
Debio 1562M is a next-generation investigational antibody-drug conjugate (ADC) consisting of a humanized monoclonal antibody (K7153B[huCD37-3] or naratuximab) directed against CD37 and conjugated to a peptidic cleavable linker (Multilink™)* bearing a maytansinoid cytotoxic payload (DM1).
No takes yet. Share an insight, caveat, or question.
Peter Hofland (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: